Enhertu Nabs A First With UK Standalone Approval
Advanced Breast Cancer Treatment Is First New Cancer Drug Approved In 2021
The UK conditional approval of Daiichi Sankyo/AstraZeneca’s advanced breast cancer drug Enhertu was issued in accordance with “transitional provisions” that apply to drugs that received a positive opinion from the European Medicines Agency before the end of the Brexit transition period.
